Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1970 1
1971 1
1973 3
1974 2
1976 1
1977 1
1978 1
1981 1
1982 1
1983 2
1985 2
1986 2
1987 1
1988 2
1989 2
1990 2
1991 6
1992 5
1993 5
1994 2
1995 3
1996 6
1997 14
1998 12
1999 11
2000 2
2001 5
2002 5
2003 7
2004 8
2005 10
2006 14
2007 6
2008 13
2009 11
2010 13
2011 17
2012 20
2013 15
2014 16
2015 12
2016 9
2017 11
2018 13
2019 16
2020 18
2021 15
2022 15
2023 14
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Schwann cell-secreted PGE2 promotes sensory neuron excitability during development.
Kantarci H, Elvira PD, Thottumkara AP, O'Connell EM, Iyer M, Donovan LJ, Dugan MQ, Ambiel N, Granados A, Zeng H, Saw NL, Brosius Lutz A, Sloan SA, Gray EE, Tran KV, Vichare A, Yeh AK, Münch AE, Huber M, Agrawal A, Morri M, Zhong H, Shamloo M, Anderson TA, Tawfik VL, Du Bois J, Zuchero JB. Kantarci H, et al. Among authors: dugan mq. Cell. 2024 Aug 22;187(17):4690-4712.e30. doi: 10.1016/j.cell.2024.07.033. Epub 2024 Aug 13. Cell. 2024. PMID: 39142281
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. Soria JC, et al. Among authors: dugan m. Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Lancet. 2017. PMID: 28126333 Clinical Trial.
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Posner MR, et al. Among authors: dugan m. N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956. N Engl J Med. 2007. PMID: 17960013 Free article. Clinical Trial.
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel AH, Brägelmann J, Wagener-Ryczek S, Merkelbach-Bruse S, Wolf J, Buettner R, Catanzariti L, Scheffler M, Hillmer AM. Arolt C, et al. Among authors: dugan m. J Thorac Oncol. 2023 Nov;18(11):1550-1567. doi: 10.1016/j.jtho.2023.07.016. Epub 2023 Jul 18. J Thorac Oncol. 2023. PMID: 37473958 Free article.
Pemmican, an endurance food: Past and present.
Ngapo TM, Champagne C, Chilian C, Dugan MER, Gariépy S, Vahmani P, Bilodeau P. Ngapo TM, et al. Among authors: dugan mer. Meat Sci. 2021 Aug;178:108526. doi: 10.1016/j.meatsci.2021.108526. Epub 2021 Apr 24. Meat Sci. 2021. PMID: 33945979 Review.
Trans-10 18:1 in ruminant meats: A review.
Alves SP, Vahmani P, Mapiye C, McAllister TA, Bessa RJB, Dugan MER. Alves SP, et al. Among authors: dugan mer. Lipids. 2021 Nov;56(6):539-562. doi: 10.1002/lipd.12324. Epub 2021 Oct 4. Lipids. 2021. PMID: 34608647 Review.
359 results